A statistician's perspective on biomarkers in drug development

Pharm Stat. 2011 Nov-Dec;10(6):494-507. doi: 10.1002/pst.532. Epub 2011 Dec 8.

Abstract

Biomarkers play an increasingly important role in many aspects of pharmaceutical discovery and development, including personalized medicine and the assessment of safety data, with heavy reliance being placed on their delivery. Statisticians have a fundamental role to play in ensuring that biomarkers and the data they generate are used appropriately and to address relevant objectives such as the estimation of biological effects or the forecast of outcomes so that claims of predictivity or surrogacy are only made based upon sound scientific arguments. This includes ensuring that studies are designed to answer specific and pertinent questions, that the analyses performed account for all levels and sources of variability and that the conclusions drawn are robust in the presence of multiplicity and confounding factors, especially as many biomarkers are multidimensional or may be an indirect measure of the clinical outcome. In all of these areas, as in any area of drug development, statistical best practice incorporating both scientific rigor and a practical understanding of the situation should be followed. This article is intended as an introduction for statisticians embarking upon biomarker-based work and discusses these issues from a practising statistician's perspective with reference to examples.

Publication types

  • Review

MeSH terms

  • Biomarkers / analysis*
  • Drug Discovery / statistics & numerical data*
  • Humans
  • Precision Medicine / methods
  • Precision Medicine / statistics & numerical data
  • Research Design / statistics & numerical data
  • Toxicity Tests / statistics & numerical data

Substances

  • Biomarkers